Double-recognition-system test strip for trace fentanyl in urine and preparation method of double-recognition-system test strip
By using a fentanyl test strip with a dual recognition system in urine, combined with a lateral immunochromatography platform, the problem of insufficient detection sensitivity in the existing technology is solved, and the high frequency of trace fentanyl is achieved Quick sensitivity detection, suitable for supervision and management and home use.
Patent Information
- Application Number
- CN202411138405.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-19
- Publication Date
- 2024-11-12
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing fentanyl detection methods are difficult to meet high standards in terms of sensitivity, especially the need for rapid screening of trace fentanyl. Traditional methods have problems such as high cost, complex operation, and are not suitable for real-time detection.
Using a double-identification system trace fentanyl test strip in urine, the sample pad, gold standard pad, NC membrane and water absorption pad are assembled on the PVC base plate, and the secondary antibody labeled colloid is modified with fentanyl monoclonal antibody and biotin. Gold is subjected to double-labeling treatment, combined with a lateral immunochromatography platform to achieve rapid detection of fentanyl.
It improves the sensitivity of fentanyl detection and reaches the detection limit of 1ng/mL. It has low cost, good specificity and stability. It is suitable for supervision and management and home use, meeting the needs of rapid detection.
Smart Images

Figure CN118937665A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of detection technology, and in particular relates to a double recognition system urine trace fentanyl test strip and a preparation method thereof. Background Art
[0002] Fentanyl is a synthetic opioid with a chemical formula of C 22 H 28 N2O is used as an anesthetic and analgesic in medicine. It is also used to prevent or alleviate postoperative delirium. It can also be used in combination with anesthetics as an auxiliary drug for anesthesia. It is combined with droperidol to make a "sedative analgesic" for large-area dressing changes and analgesia for minor surgeries. Fentanyl is mainly metabolized in the liver, and the metabolites and the original drug are excreted through the urine by the kidneys.
[0003] Currently developed methods for measuring fentanyl or fentanyl analogs, such as gas-liquid chromatography, surface-enhanced Raman spectroscopy, direct analysis by thermal desorption based on real-time mass spectrometry (TD-DART-MS) and ion mobility spectrometry (IMS), although these techniques have been successfully applied in many laboratories, are not always available for real-time routine inspections and often require technical expertise. These instruments also cannot be scaled down to portable devices for forensic in-situ detection or medical real-time detection. In parallel with quantitative methods, semi-quantitative methods have been used as routine urine toxicology screening in hospitals using enzyme-mediated immunoassays such as enzyme-linked immunosorbent assay (ELISA) and radioimmunoassay. However, despite the many advantages of these methods, When it comes to immune enzyme elements, many well-known disadvantages need to be considered, such as the need for refrigeration during transportation and storage, the production characteristics of antibodies are long manufacturing cycles, high costs, and inability to meet the requirements of clinical rapid detection. At the same time, there are also reports on colloidal gold lateral chromatography fentanyl detection methods and products based on the principle of immune recognition. Some research results use a pre-incubation method combined with lateral chromatography to achieve the detection of fentanyl based on the principle of colorimetry (linear gradient response, but not elimination), with a sensitivity of 2ng / mL, or worse sensitivity results. Existing methods cannot meet the requirements for export to developed countries such as the United States in terms of detection sensitivity, and 1ng / mL completely eliminates the line, which has a serious limiting effect on the application of technology and products.
[0004] According to the United Nations Office on Drugs and Crime, nearly 5% of the world's adult population regularly takes illicit drugs. Opioid-related deaths are reported to be the largest factor in drug-related deaths worldwide, with both prescription and over-the-counter (illegal) opioids contributing to these deaths. As the demand for drug testing increases, it is of great significance to develop a low-cost, easy-to-use method that can quickly screen for trace amounts of fentanyl in urine, unlike traditional rapid testing methods. Summary of the invention
[0005] The purpose of the present invention is to provide a double recognition system urine trace fentanyl test strip and a preparation method thereof, so as to solve the problem of difficulty in detecting trace fentanyl.
[0006] The purpose of the present invention can be achieved by the following technical solutions:
[0007] A double recognition system urine trace fentanyl test strip, comprising a sample pad, a gold label pad, an NC membrane and a water absorbent pad, which are sequentially assembled on a PVC base plate to obtain a fentanyl test strip;
[0008] The gold-labeled pad comprises a conjugation pad 1 and a conjugation pad 2; the conjugation pad 1 is obtained by dripping 20-40 nm colloidal gold labeled with fentanyl antibody on glass fiber; the conjugation pad is obtained by dripping 30-50 nm colloidal gold labeled with biotin-modified secondary antibody on glass fiber;
[0009] The fentanyl antigen on the NC membrane is used as the detection line (T line), and the streptavidin is used as the quality control line (C line).
[0010] Further, in the fentanyl antibody-labeled 20-40 nm colloidal gold, the fentanyl antibody is a fentanyl monoclonal antibody (Ab-FEN), and the fentanyl monoclonal antibody in each 6 μL 20-40 nm colloidal gold is 0.07-0.09 μg;
[0011] In the biotin-modified secondary antibody labeled with 30-50 nm colloidal gold, the biotin-modified secondary antibody is a biotin-modified goat anti-mouse antibody (GAM-BIO), and the amount of the biotin-modified goat anti-mouse antibody added to each 1000 μL 30-50 nm colloidal gold is 3-5 μg.
[0012] Further, the concentration of the quality control line (C line) is 1 mg / mL;
[0013] The test line (T line) concentration is 0.03 mg / mL;
[0014] The distance between the quality control line (C line) and the detection line (T line) is 8 mm.
[0015] The preparation method of the double recognition system trace fentanyl test strip in urine comprises the following steps:
[0016] The first step is to combine fentanyl monoclonal antibody with 20-40nm colloidal gold to prepare fentanyl antibody labeled 20-40nm colloidal gold;
[0017] The biotin-modified goat anti-mouse antibody is combined with 30-50 nm colloidal gold to prepare a biotin-modified secondary antibody labeled with 30-50 nm colloidal gold;
[0018] Step 2: Sample pad treatment: soak the sample pad in the sample pad treatment solution, take it out and dry it;
[0019] NC membrane treatment: dilute streptavidin with PB buffer solution, dilute fentanyl antigen with PB buffer solution, and pipette them into the corresponding membrane stripping instrument pipeline for stripping. The fentanyl antigen on the NC membrane is used as the test line (T line), and streptavidin is used as the quality control line (C line), and then dried;
[0020] Gold-labeled pad treatment: soak the glass fiber in the gold-labeled pad treatment solution, take it out and dry it, label 20-40 nm colloidal gold with fentanyl antibody and perform drop pad treatment on the glass fiber to obtain conjugate pad 1; label 30-50 nm colloidal gold with biotin-modified secondary antibody and perform drop pad treatment on the glass fiber to obtain conjugate pad 2;
[0021] Step 3: Assembly:
[0022] Assemble the sample pad, NC membrane and water absorbent pad on the PVC base plate from bottom to top, with the water absorbent pad and NC membrane overlapping by 2 mm. Then put it into the strip cutter and cut it into 3 mm wide test strips; assemble the conjugate pad 1 and conjugate pad 2 between the sample pad and NC membrane, with an overlapping part of 2 mm; finally, install the card shell, seal it with a tin foil bag, and put in a desiccant.
[0023] Furthermore, the fentanyl antibody labeled 20-40 nm colloidal gold in the first step is prepared by the following steps:
[0024] Add BB buffer to 20-40nm colloidal gold, add fentanyl monoclonal antibody (Ab-FEN), and incubate at room temperature; then add BSA (bovine serum albumin) to block, centrifuge, remove the supernatant, dilute with resuspending solution, treat with a drop pad, and dry for use.
[0025] Furthermore, the biotin-modified secondary antibody labeled with 30-50 nm colloidal gold in the first step is prepared by the following steps:
[0026] Add K2CO3 to 30-50nm colloidal gold, then add biotin (Bio) modified goat anti-mouse antibody (GAM) and incubate at room temperature; add BSA (bovine serum albumin) for blocking, centrifuge, remove the supernatant, dilute with resuspending solution, treat with a drop pad, and dry for later use.
[0027] Furthermore, the concentration of the BB buffer solution is 10 mM, and the pH value of the BB buffer solution is 7.4.
[0028] Furthermore, the solvent in the sample pad treatment solution in the second step is water, and each liter of the sample pad treatment solution contains 8.75 g NaCl, 50 mL 1 M Tris-HCl and 2.5 mL Triton X-100;
[0029] The solvent in the gold-labeled pad treatment solution in the second step is 10 mM Tris-HCl, and each liter of the gold-labeled pad treatment solution contains 50 g sucrose, 10 g trehalose, and 3 mL Tween-20;
[0030] The solvent in the resuspension solution is PBS buffer solution, and each liter of the resuspension solution contains 5g of sodium caseinate (C-Na) and 0.01mol of sodium hydroxide. During the preparation process, the temperature is raised to 180°C for heating and dissolution.
[0031] The concentration of PBS buffer solution was 10 mM.
[0032] Furthermore, in the second step, the concentration of the PB buffer solution is 10 mM, and the pH value of the PB buffer solution is 7.4;
[0033] The PB buffer solution contains 3% by mass of trehalose;
[0034] Fentanyl antigen was diluted to 0.03 mg / L;
[0035] Streptavidin was diluted to 1 mg / L.
[0036] Furthermore, the water output of the quality control line (C line) in the second step is 0.5 μL / cm;
[0037] The water output of the detection line (T line) is 0.7 μL / cm.
[0038] Furthermore, the pH value of the 10 mM PBS buffer solution is 7.4.
[0039] Beneficial effects of the present invention:
[0040] 1) The present invention is based on a lateral immunochromatography platform and develops a trace fentanyl detection test strip based on the principle of simultaneous double labeling. By using the simultaneous immunochromatographic double labeling system, the insignificant immune competition detection signal caused by trace fentanyl can be enhanced by adding the sample once, thereby improving the detection sensitivity of the fentanyl detection test strip and meeting a higher level of detection requirements, with a detection limit of 1 ng / mL.
[0041] 2) The lateral immunochromatography method is low in cost and has good specificity and stability. It can achieve the purpose of rapid detection and can effectively meet the needs of supervisory and management departments, enterprises, and individual families. BRIEF DESCRIPTION OF THE DRAWINGS
[0042] The present invention will be further described below in conjunction with the accompanying drawings.
[0043] Figure 1 is a schematic diagram of the principle of double labeling in Example 1 of the present invention;
[0044] Figure 2 1 is a graph showing the test results of the detection lines of different concentrations in Example 2 of the present invention;
[0045] Figure 3 is a graph showing the test results of fentanyl antibody-labeled gold nanoparticles at different concentrations in Example 2 of the present invention;
[0046] Figure 4 This is a graph showing the detection limit results of spiked samples in Example 3 of the present invention;
[0047] Figure 5 is a graph showing the detection results of fentanyl derivatives in Example 4 of the present invention;
[0048] Figure 6 This is a diagram of interference specificity detection results of Example 4 of the present invention. DETAILED DESCRIPTION
[0049] The following will be combined with the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0050] In the embodiment, 50 nm colloidal gold and 40 nm colloidal gold were taken as examples for testing, wherein the 50 nm colloidal gold was homemade, and the 40 nm colloidal gold was purchased from Zhengzhou Lingsi Biology.
[0051] The specific steps for preparing 50nm colloidal gold are as follows: the volume of the prepared colloidal gold is 150mL, so a 250mL conical flask is selected. In order to make the preparation of colloidal gold pollution-free, the conical flask and the stirrer need to be soaked in aqua regia for 24 hours before preparing the colloidal gold, and then the conical flask and the stirrer are rinsed with tap water and double distilled water for 3 times, and about two-thirds of the volume of double distilled water is added to the conical flask, and the conical flask is sealed with plastic wrap and placed on a magnetic heating stirrer for heating. After the double distilled water boils, it is poured out and new double distilled water is added. After this is repeated 3 times, the conical flask is set aside; 150mL of double distilled water is added to the cleaned conical flask, and then 1.5mL of 40mM chloroauric acid aqueous solution is added, and the heating and speed switches of the magnetic heating stirrer are turned on to make the chloroauric acid dispersed evenly, and then the stirring is turned off; when more bubbles appear on the stirrer in the mixed solution and the solution reaches a slightly boiling state, 1.8mL of 1% trisodium citrate solution, keep heating and start rapid stirring. Soon after the addition of trisodium citrate to the chloroauric acid solution, a series of color changes began to occur, from the initial light yellow solution to gradually turn purple, and the entire change process lasted for 2-3 minutes. After the color stabilized, stop heating and continue stirring for 5 minutes, then let it stand at room temperature to allow it to cool naturally, and finally put the prepared 50nm colloidal gold (AuNPs) into a 4°C refrigerator for storage.
[0052] Example 1
[0053] A. Preparation of reagent materials and equipment;
[0054] B. Preparation of gold-labeled antibodies;
[0055] C. Preparation of test strips;
[0056] D. Assembly and sealing of test strips.
[0057] The details of step A are as follows:
[0058] A1) Reagents and materials mainly include: preparation of 50nm colloidal gold, 40nm colloidal gold, nitrocellulose membrane, sample pad, absorbent pad, bottom plate, fentanyl antibody, fentanyl coating source, streptavidin, goat anti-mouse modified biotin, bovine serum albumin, sodium caseinate, potassium carbonate, sucrose, trehalose; reagents include: 10mM PB buffer solution, 10mM BB buffer solution, 10mM PBS buffer solution, gold pad treatment solution, sample pad treatment solution and resuspension solution. Equipment mainly includes: high-speed centrifuge, vortex shaker, membrane strip cutter, automatic membrane stripper, air drying oven and constant temperature magnetic stirrer.
[0059] A2) Gold label pad treatment solution: 10 g sucrose, 2 g trehalose, and 600 μL Tween-20 were dissolved by ultrasonic treatment, and finally the volume was adjusted to 200 mL with 10 mM Tris-HCl;
[0060] A3) Sample pad treatment solution: 1.75 g NaCl, 10 mL 1 M Tris-HCl, 500 μL Triton X-100, sonicate to dissolve, and finally dilute to 200 mL with pure water;
[0061] A4) Resuspension solution: Take 0.05 g of casein sodium in a 15 mL transparent glass bottle, add 100 μL of 1 M sodium hydroxide, and dilute to 10 mL with 10 mM PBS buffer solution. Then heat on a 180°C constant temperature magnetic stirrer to dissolve, finally add water to 10 mL, and add 0.3 g of trehalose.
[0062] The pH values of the 10 mM PB buffer solution, the 10 mM BB buffer solution, and the 10 mM PBS buffer solution are all 7.4.
[0063] Step B, double labeling Figure 1 As shown:
[0064] B1) Fentanyl antibody labeled 40nm colloidal gold: Take 6μL 40nm colloidal gold (referred to as AuNPs-1), add 1000μL BB buffer (10mM) and 0.07μg fentanyl antibody (Ab-FEN), incubate at room temperature for 30min. Then add 100μL 10% BSA to block for 10min. Centrifuge at 9600rmp, 4℃, 10min, remove the supernatant, add 100μL resuspension solution to dilute, and 4μL for drip pad treatment. Dry at 37℃ for use.
[0065] B2) Biotin-modified secondary antibody labeled with 50nm colloidal gold: Take 1000μL 50nm colloidal gold (referred to as AuNPs-2), add 5μL K2CO3 (0.1M) and then add 3μg biotin (Bio)-modified goat anti-mouse antibody (GAM) and incubate at room temperature for 30min; add 100μL 10% BSA to block for 10min. Centrifuge at 9600rmp, 4℃, 10min, remove the supernatant, add 100μL resuspension solution, and 4μL for drop pad treatment. Dry at 37℃ for later use.
[0066] The specific steps described in step C are as follows:
[0067] C1) NC membrane scratching process: A nitrocellulose membrane with a creeping speed of 140 was selected for spraying. Fentanyl antigen was diluted to 0.03 mg / ml using 10 mM PB (pH = 7.4, containing 3% trehalose), and streptavidin (SAV) was diluted to 1 mg / ml; fentanyl antigen was used as T line and streptavidin as C line, and they were respectively sucked back into the corresponding membrane scratching instrument pipeline for scratching. The water output of C line was 0.5 μL / cm, the water output of T line was 0.7 μL / cm, the distance between C line and T line was 8 mm, and the membrane was dried at 55°C for 48 hours.
[0068] C2) Gold label pad: Cut the glass fiber membrane into 30*0.6cm, soak it in the gold label pad treatment solution for 2h, take it out and dry it at 37℃ overnight, and then cut it into 3*6mm.
[0069] C3) Sample pad: Cut the glass fiber membrane into 30*1.8 cm pieces, soak it in the sample pad treatment solution for 2 h, and dry it at 37°C overnight.
[0070] The test strips described in step D are assembled and packaged in the following specific steps: stick the sample pad, gold label pad 1, gold label pad 2, NC film and sample pad on the PVC bottom plate from bottom to top, overlapping by 2 mm, and finally packaged in a shell. Put it in an aluminum foil bag, add desiccant and seal it.
[0071] Example 2
[0072] Optimization of test strip conditions
[0073] The preparation of the fentanyl test strip has the following specific differences, and other parts not mentioned are the same as those in Example 1.
[0074] The test line (T line) concentrations are 0.03, 0.05, and 0.1 mg / mL. Figure 2 shown.
[0075] The concentrations of fentanyl antibody-labeled gold nanoparticles were 0.05, 0.07, and 0.1 μg, respectively. Figure 3 As shown in the figure, the optimal T-line concentration of the fentanyl test strip was 0.03 mg / mL and the antibody dosage was 0.07 μg.
[0076] Example 3
[0077] Sensitivity determination
[0078] Samples with final concentrations of 0, 0.75, 1, and 1.25 ng / mL (fentanyl content) were used for testing. Figure 4As shown: when the concentration is 0.75 ng / mL, the T line still appears weakly, which does not meet the elimination requirement. At 1 ng / mL, the T line does not appear. It can be obtained that the detection limit of fentanyl in urine samples of the present invention is 1 ng / mL.
[0079] Example 4
[0080] Specificity verification
[0081] The present invention was tested for cross-interference and interference specificity, and the test strip preparation process remained unchanged. Fentanyl derivatives used in cross-interference included remifentanil, sufentanil, alfentanil, carfentanil and 3-methylfentanyl. The results are shown in Figure 5 As shown: when detecting fentanyl derivatives, the T line has different degrees of line elimination, but the degree of line elimination is not as obvious as fentanyl, indicating that on the one hand, the present invention can perform group screening of fentanyl-like substances, and at the same time, it can also qualitatively distinguish fentanyl and analogs.
[0082] In the interference specificity, midazolam, MDMA, THC, ketamine and morphine were selected as targets for detection. Figure 6 As shown: it does not cause the T-line disappearance phenomenon and is not detected, indicating that the invention has good specificity.
[0083] It should be noted that, in this article, relational terms such as first and second, etc. are only used to distinguish one entity or operation from another entity or operation, and do not necessarily require or imply any such actual relationship or order between these entities or operations. Moreover, the terms "include", "comprise" or any other variants thereof are intended to cover non-exclusive inclusion, so that a process, method, article or device including a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements inherent to such process, method, article or device.
[0084] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.
Claims
1. A dual recognition system test strip for trace fentanyl in urine, characterized in that: It includes a sample pad, a gold label pad, an NC membrane and a water absorbent pad, which are assembled on a PVC base plate in sequence to obtain a fentanyl test strip; The fentanyl antigen on the NC membrane is used as a detection line, and streptavidin is used as a quality control line; The gold-labeled pad comprises a conjugation pad 1 and a conjugation pad 2; the conjugation pad 1 is obtained by dripping 20-40 nm colloidal gold labeled with fentanyl antibody on glass fiber; and the conjugation pad is obtained by dripping 30-50 nm colloidal gold labeled with biotin-modified secondary antibody on glass fiber.
2. The dual recognition system urine trace fentanyl test strip according to claim 1, characterized in that: In the fentanyl antibody-labeled 20-40 nm colloidal gold, the fentanyl antibody is a fentanyl monoclonal antibody, and the fentanyl monoclonal antibody in each 6 μL 20-40 nm colloidal gold is 0.07-0.09 μg; In the biotin-modified secondary antibody labeled with 30-50 nm colloidal gold, the biotin-modified secondary antibody is a biotin-modified goat anti-mouse antibody, and the amount of the biotin-modified goat anti-mouse antibody added in each 1000 μL 30-50 nm colloidal gold is 3-5 μg.
3. The dual recognition system urine trace fentanyl test strip according to claim 1, characterized in that: The quality control line concentration is 1 mg / mL; The test line concentration is 0.03 mg / mL; The distance between the quality control line and the detection line is 8 mm.
4. The method for preparing a dual recognition system urine trace fentanyl test strip according to any one of claims 1 to 3, characterized in that: The steps include: The first step is to prepare fentanyl antibody labeled with 20-40nm colloidal gold; Prepare biotin-modified secondary antibody labeled with 30-50nm colloidal gold; Step 2: Sample pad treatment: soak the sample pad in the sample pad treatment solution, take it out and dry it; NC membrane treatment: dilute streptavidin with PB buffer solution, dilute fentanyl antigen with PB buffer solution, and pipette them into the corresponding membrane stripping instrument pipelines for stripping. The fentanyl antigen on the NC membrane is used as the detection line, and streptavidin is used as the quality control line. Dry it. Gold-labeled pad treatment: soak the glass fiber in the gold-labeled pad treatment solution, take it out and dry it, label 20-40 nm colloidal gold with fentanyl antibody and perform drop pad treatment on the glass fiber to obtain conjugate pad 1; label 30-50 nm colloidal gold with biotin-modified secondary antibody and perform drop pad treatment on the glass fiber to obtain conjugate pad 2; Step 3: Assembly.
5. The method for preparing the double recognition system trace fentanyl test strip in urine according to claim 4, characterized in that: The assembly comprises the following steps: assembling the sample pad, the NC membrane and the water absorbent pad on the PVC bottom plate in order from bottom to top, respectively, with the water absorbent pad and the NC membrane overlapping by 2 mm; Then put it into the strip cutter and cut it into 3mm wide test strips; assemble the conjugate pad 1 and conjugate pad 2 between the sample pad and the NC membrane respectively, with an overlapping part of 2mm; finally, put it into the card shell, package it with a tin foil bag, and put in the desiccant.
6. The method for preparing a dual recognition system urine trace fentanyl test strip according to claim 4, characterized in that: The fentanyl antibody-labeled 20-40 nm colloidal gold described in the first step is prepared by the following steps: Add BB buffer to 20-40 nm colloidal gold, add fentanyl monoclonal antibody, and incubate at room temperature; then add BSA to block, centrifuge, remove the supernatant, add resuspension solution to dilute, perform drop pad treatment, and dry for later use.
7. The method for preparing a dual recognition system urine trace fentanyl test strip according to claim 4, characterized in that: The biotin-modified secondary antibody labeled with 30-50 nm colloidal gold in the first step is prepared by the following steps: Add K2CO3 to 30-50nm colloidal gold, then add biotin-modified goat anti-mouse antibody and incubate at room temperature; add BSA to block, centrifuge, remove the supernatant, add resuspension solution to dilute, then perform drop pad treatment, and dry for later use.
8. The method for preparing a dual recognition system urine trace fentanyl test strip according to claim 6, characterized in that: The concentration of the BB buffer solution is 10 mM, and the pH value of the BB buffer solution is 7.4; The solvent in the resuspension solution is PBS buffer solution, and each liter of the resuspension solution contains 5g of sodium caseinate and 0.01mol of sodium hydroxide. During the preparation process, the temperature is raised to 180°C to dissolve; The concentration of the PBS buffer solution is 10 mM.
9. The method for preparing a dual recognition system urine trace fentanyl test strip according to claim 4, characterized in that: The solvent in the sample pad treatment solution in the second step is water, and each liter of the sample pad treatment solution contains 8.75 g NaCl, 50 mL 1 M Tris-HCl and 2.5 mL Triton X-100; The solvent in the gold-labeled pad treatment solution in the second step is 10 mM Tris-HCl, and each liter of the gold-labeled pad treatment solution contains 50 g sucrose, 10 g trehalose, and 3 mL Tween-20.
10. The method for preparing a dual recognition system urine trace fentanyl test strip according to claim 4, characterized in that: The water output of the quality control line described in the second step is 0.5 μL / cm; The water output of the test line is 0.7 μL / cm; In the second step, the concentration of the PB buffer solution is 10 mM, and the pH value of the PB buffer solution is 7.4; The PB buffer solution contains 3% by mass of trehalose; Fentanyl antigen was diluted to 0.03 mg / L; Streptavidin was diluted to 1 mg / L.
Citation Information
Patent Citations
Preparation method of immunofluorescent test strip with high precision
CN109884294A
Colloidal gold immunochromatography test paper for combined diagnosis of COVID-19 and mycoplasma pneumoniae and preparation method thereof
CN111426830A
Artificial hapten and artificial antigen of fentanyl as well as preparation method and application of artificial hapten and artificial antigen
CN117126102A
Test paper for simultaneously detecting toluthiazine and fentanyl as well as preparation method and application of test paper
CN118209740A
Forensic test for human saliva
US20070092977A1
